Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2011: 105/2 (Feb) pp. 207-386
Pages: 295-301

Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia

HABENOX*: A randomised multicentre trial

J. Visser (1), V.-M. Ulander (2), F. M. Helmerhorst (1), K. Lampinen (3), L. Morin-Papunen (4), K. W. M. Bloemenkamp (1), R. J. Kaaja (2)

(1) Department of Obstetrics, Gynaecology and Reproductive Medicine, Leiden University Medical Center, Leiden, the Netherlands; (2) Department of Obstetrics and Gynaecology, Helsinki University Hospital, Helsinki, Finland; (3) Department of Obstetrics and Gynaecology, Karolinska University Hospital, Stockholm, Sweden; (4) Department of Obstetrics and Gynaecology, Oulu University Hospital, Oulu, Finland


Clinical trials, thrombophilia, pregnancy, heparins/LMWH


Recurrent miscarriage affects 1–2% of women. In more than half of all recurrent miscarriage the cause still remains uncertain. Thrombophilia has been identified in about 50% of women with recurrent miscarriage and thromboprophylaxis has been suggested as an option of treatment. A randomised double-blind (for aspirin) multicentre trial was performed among 207 women with three or more consecutive first trimester (<13 weeks) miscarriages, two or more second trimester (13–24 weeks) miscarriages or one third trimester fetal loss combined with one first trimester miscarriage. Women were analysed for thrombophilia. After complete work-up, women were randomly allocated before seven weeks’ gestation to either enoxaparin 40 mg and placebo (n=68), enoxaparin 40 mg and aspirin 100 mg (n=63) or aspirin 100 mg (n=76). The primary outcome was live-birth rate. Secondary outcomes were pregnancy complications, neonatal outcome and adverse effects. The trial was ended prematurely because of slow recruitment. A live birth rate of 71% [relative risk (RR) 1.17, 95% confidence interval (CI) 0.92–1.48] was found for enoxaparin and placebo and 65% [RR 1.08, 95% CI 0.83–1.39] for enoxaparin and aspirin when compared to aspirin alone (61%, reference group). In the whole study group the live birth rate was 65% (95% CI 58.66–71.74) for women with three or more miscarriages (n=204). No difference in pregnancy complications, neonatal outcome or adverse effects was observed. No significant difference in live birth rate was found with enoxaparin treatment versus aspirin or a combination of both versus aspirin in women with recurrent miscarriage.

You may also be interested in...

I. Pabinger

Hämostaseologie 2008 28 3: 130-134

Willem J. Kist 1, Nard G. Janssen 1, Jakoba J. Kalk 1, William M. Hague 2, Gustaaf A. Dekker 3, Johanna I. P. de Vries1

Thromb Haemost 2008 99 1: 77-85

André Kher 1, Rupert Bauersachs 2, Jorn Dalsgaard Nielsen3

Thromb Haemost 2007 97 4: 505-513